Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – November 13, 2024 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://oklahoma.zoom.us/webinar/register/WN_94lCoSe9Ty2msgsLMqg2Ww
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 958 2294 2095
Passcode: 65079339

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. October 9, 2024 DUR Board Meeting Minutes
   B. October 9, 2024 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. Metts, Dr. O'Halloran, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Adherence to Asthma Maintenance Medications Prior to Adding on Biologic Therapy – See Appendix B**
   A. Pharmacy Help Desk Activity for October 2024
   B. Medication Coverage Activity for October 2024
   C. Adherence to Asthma Maintenance Medications Prior to Adding on Biologic Therapy

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

5. **Action Item – Approval of 2025 Drug Utilization Review (DUR) Board Meeting Dates – See Appendix C**
   A. 2025 DUR Board Meeting Dates

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Bimzelx® (Bimekizumab-bkzx), Leqselvi™ (Deuruxolitinib), Omvoh™ (Mirikizumab-mrkz), Otulfi™ (Ustekinumab-aauz), Pyzchiva® (Ustekinumab-ttwe), Rinvoq® LQ (Upadacitinib Oral Solution), Selarsdi™ (Ustekinumab-aekn), Simlandi® (Adalimumab-ryvk), Tyenne® (Tocilizumab-aazg), Velsipity™ (Etrasimod), Wezlana™ (Ustekinumab-auub), and Zymfentra™ (Infliximab-dyyb) and Update the Approval Criteria for the Targeted Immunomodulator Agents – See Appendix D**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Rivfloza® (Nedosiran) – See Appendix E**
   A. Market News and Updates
   B. Rivfloza® (Nedosiran) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Casgevy™ (Exagamglogene Autotemcel), Lyfgenia® (Lovotibeglogene Autotemcel), Vafseo® (Vadadustat), and Xromi® (Hydroxyurea Oral Solution) and Update the Approval Criteria for the Anemia Medications – See Appendix F**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

9. **Action Item – Annual Review of Multiple Myeloma Medications – See Appendix G**
   A. Current Prior Authorization Criteria
   B. Utilization of Multiple Myeloma Medications
   C. Prior Authorization of Multiple Myeloma Medications
   D. Market News and Updates
   E. College of Pharmacy Recommendations
   F. Utilization Details of Multiple Myeloma Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

10. **Action Item – Annual Review of Lambert-Eaton Myasthenic Syndrome (LEMS) Medications – See Appendix H**
   A. Current Prior Authorization Criteria
   B. Utilization of LEMS Medications
   C. Prior Authorization of LEMS Medications

D. Market News and Updates
E. College of Pharmacy Recommendation
F. Utilization Details of LEMS Medications

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

11. Action Item – Annual Review of Hereditary Angioedema (HAE) Medications – See Appendix I

A. Current Prior Authorization Criteria
B. Utilization of HAE Medications
C. Prior Authorization of HAE Medications
D. Market News and Updates
E. Cost Comparison: Icatibant Products
F. College of Pharmacy Recommendations
G. Utilization Details of HAE Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

12. 30-Day Notice to Prior Authorize Nemluvio® (Nemolizumab-ilto) – See Appendix J

A. Introduction
B. Nemluvio® (Nemolizumab-ilto) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

13. Annual Review of Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications and 30-Day Notice to Prior Authorize Ohtuvayre™ (Ensifentrine) – See Appendix K

A. Current Prior Authorization Criteria
B. Utilization of Asthma and COPD Maintenance Medications
C. Prior Authorization of Asthma and COPD Maintenance Medications
D. Market News and Updates
E. Ohtuvayre™ (Ensifentrine) Product Summary
F. College of Pharmacy Recommendation
G. Utilization Details of Asthma and COPD Maintenance Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

14. Annual Review of Atopic Dermatitis (AD) Medications and 30-Day Notice to Prior Authorize Ebglyss™ (Lebrikizumab-lbkz) – See Appendix L

A. Current Prior Authorization Criteria
B. Utilization of AD Medications
C. Prior Authorization of AD Medications
D. Market News and Updates
E. Ebglyss™ (Lebrikizumab-lbkz) Product Summary
F. Cost Comparisons
G. College of Pharmacy Recommendations
H. Utilization Details of AD Medications

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

15. Annual Review of Sohonos™ (Palovarotene) – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of Sohonos™ (Palovarotene)
C. Prior Authorization of Sohonos™ (Palovarotene)
D. Market News and Updates
E. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)

A. Antidepressants
B. Complement Inhibitors and Miscellaneous Immunomodulatory Agents
C. Lysosomal Storage Disease Medications
D. Osteoporosis Medications

*Future product and class reviews subject to change.

18. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization reported in this packet is based solely on the data provided by the SoonerSelect plans.